OPC-108459

Phase 1Small molecule

Otsuka

OPC-108459 is one of 23 small molecule programs targeting Atrial Fibrillation. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atrial FibrillationActive, not recruiting

Atrial FibrillationPhase 1

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 2

Anticoagulants

Sanofi

Preclinical

2 3

Direct Anticoagulant

Bayer

Preclinical

1 4

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 5

Statin

Bristol-Myers Squibb

Preclinical

1 6

Warfarin Sodium

Boehringer Ingelheim

Preclinical

3 7

Magnesium SO4

HHospital de Base

Preclinical

2 8

Medication

NNYU Langone Health

Preclinical

1 9

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

1 10

OPC-108459

Otsuka

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atrial Fibrillation2 trials

A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)

Completed· Otsuka logo

Otsuka·Phase 1·NCT02069119·48 enrolled

Ascending Dose Study of OPC-108459 Intravenous Infusions in Patients With Paroxysmal and Persistent Atrial Fibrillation

Terminated· Otsuka logo

Otsuka·Phase 1·NCT01483183·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for OPC-108459. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPC-108459 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPC-108459. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Otsuka

OPC-108459

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atrial Fibrillation2 trials

References

Drug Info

Quick Facts

Related News